Literature DB >> 623339

A rating scale for emotional blunting.

R Abrams, M A Taylor.   

Abstract

Although emotional blunting has always been considered a core symptom of schizophrenia, it has been excluded from recently developed sets of diagnostic criteria because of its alleged unreliability. The authors describe a brief rating scale for emotional blunting that is highly reliable, predicts short-term treatment response, and discriminates between patients with affective disorder and schizophrenia. They suggest that this scale will permit restoration of the important criterion of emotional blunting to modern diagnostic systems, including that proposed for DSM-III.

Entities:  

Mesh:

Year:  1978        PMID: 623339     DOI: 10.1176/ajp.135.2.226

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  22 in total

Review 1.  Theoretical considerations and perspectives on the onset of action of moclobemide.

Authors:  J P Gachoud; H Mikkelsen; S Ammar; D Widlöcher; R Jouvent
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

3.  Neuroanatomical correlates of emotional blunting in behavioral variant frontotemporal dementia and early-onset Alzheimer's disease.

Authors:  Grace J Lee; Po H Lu; Michelle J Mather; Jill Shapira; Elvira Jimenez; Alex D Leow; Paul M Thompson; Mario F Mendez
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.

Authors:  Thomas H McGlashan; William T Carpenter
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

5.  Evaluation of emotional blunting in behavioral variant frontotemporal dementia compared to Alzheimer's disease.

Authors:  Aditi Joshi; Joseph P Barsuglia; Michelle J Mather; Elvira E Jimenez; Jill Shapira; Mario F Mendez
Journal:  Dement Geriatr Cogn Disord       Date:  2014-03-01       Impact factor: 2.959

6.  Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.

Authors:  E Peselow; B Angrist; A Sudilovsky; J Corwin; J Siekierski; F Trent; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Preliminary studies of clonidine in psychotic patients.

Authors:  B Angrist; M Smith; L Adler; E Peselow; J Reitano; J Rotrosen
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.

Authors:  A Wolkin; B Angrist; A Wolf; J Brodie; B Wolkin; J Jaeger; R Cancro; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Psychopathological and emotional deficits in myotonic dystrophy.

Authors:  C Bungener; R Jouvent; C Delaporte
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

10.  A subscale for negative symptoms from the Comprehensive Psychopathological Rating Scale (CPRS): a comparison with the Schedule for Assessment of Negative Symptoms (SANS).

Authors:  E Lindström; L H Lindström
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.